Rallybio Corp (RLYB) News
Filter RLYB News Items
RLYB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RLYB News Highlights
- RLYB's 30 day story count now stands at 2.
- Over the past 11 days, the trend for RLYB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CONN, ASH and RARE are the most mentioned tickers in articles about RLYB.
Latest RLYB News From Around the Web
Below are the latest news stories about RALLYBIO CORP that investors may wish to consider to help them evaluate RLYB as an investment opportunity.
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5NEW HAVEN, Conn., December 20, 2023--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated diseases. |
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual MeetingNEW HAVEN, Conn., December 09, 2023--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting, in San Diego, California. The FNAIT natural h |
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune ThrombocytopeniaNEW HAVEN, Conn., November 28, 2023--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics (PK) study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia. |
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNEW HAVEN, Conn., November 09, 2023--Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent program and corporate developments. |
Rallybio to Present at Upcoming Investor Conferences in NovemberNEW HAVEN, Conn., November 08, 2023--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: |
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual MeetingNEW HAVEN, Conn., November 02, 2023--Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, which will be held December 9-12, 2023, in San Diego, California. |
Rallybio to Present at the JonesTrading 2023 Healthcare SummitNEW HAVEN, Conn., October 03, 2023--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, "Novel Platform Technologies in Rare Disease and Oncology," at the JonesTrading 2023 Healthcare Summit on October 10, 2023 at 11:00 a.m. |
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5NEW HAVEN, Conn., September 03, 2023--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented clinical data in a poster from the Phase 1 first-in-human single ascending dose (SAD) clinical study in healthy participants of RLYB116. RLYB116 is an innovative potentially long-acting, subcutaneously injected inhibitor of C5 in develop |
Rallybio to Present at Upcoming Investor Conferences in SeptemberNEW HAVEN, Conn., August 31, 2023--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: |
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |